ZBH

Rating neutralAI Memo

Zimmer Biomet

As of 2026-10-10/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-10 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

Test of raised 2026 guidance • 2026-12-31

Base target: $97 / p=50% prob

Biggest risk

Flat Q2 adjusted EPS and just 0.1% organic constant-currency knee growth leave the core franchise vulnerable to execution disappointment; a leadership transition adds uncertainty. Company Q2 release [#8-K-2026-09-08]

Invalidation

Break below $73 or thesis failure.

What would change my mind?

Raised 2026 guidance, 4.0% Q2 organic constant-currency growth, and a robotics pipeline support a measured improvement case if commercial restructuring sustains execution. Company Q2 release Company leadership update

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-10

Base target

$97

p=50%

Bull target

$110

p=25%

Bear target

$73

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Americas restructuring and knee-sales execution
ROSA Shoulder adoption after clearance
Expected 2027 Monogram robot launch

BearKey bullets

Adjusted Q2 EPS was unchanged year over year despite higher sales; guidance execution and margin conversion remain important.
[#SEC-8K-2026-08-05]
Americas leadership restructuring could disrupt sales execution before productivity benefits appear.

WatchKey bullets

Test of raised 2026 guidance

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $97 (p=50%)

Target spread vs base: +13% / -25%

Scenario probabilities

Bull Target: $110 (p=25%)Base Target: $97 (p=50%)Bear Target: $73 (p=25%)

Commentary

The primary-source guidance raise and September reiteration are constructive, but the supplied recent-news list is largely about other issuers. No reliable current analyst-revision series, options skew, short-interest, employee score or social reading is available; zeroes denote unavailable data, not neutral measurements. The $89.14 anchor is the October 9 adjusted close, not a live quote. Despite the packet's positive deterministic prior and strong historical evidence quality, unproven forward adoption and commercial execution keep this a monitoring view.

As of 2026-10-10 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Americas restructuring and knee-sales execution
ROSA Shoulder adoption after clearance
Expected 2027 Monogram robot launch

Scenarios

Bull Target (Scenario probability)

$110 / p=25% prob

Base Target (Scenario probability)

$97 / p=50% prob

Bear Target (Scenario probability)

$73 / p=25% prob

Analysis 2026-10-10 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Test of raised 2026 guidance
Q2 organic constant-currency sales grew 4.0%, while adjusted EPS was flat year over year at $2.07. Zimmer Biomet raised its full-year organic growth outlook to 2.25%–3.25% and adjusted EPS outlook to $8.47–$8.59, then reiterated that outlook in September. December 31 is a fiscal-year-end monitoring marker, not an announced results date. [#SEC-8K-2026-08-05] Company Q2 release Company September update
Prob 65.00% • Move 6.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

Americas restructuring and knee-sales execution
2026-12-31
The September filing disclosed restructuring of Kevin Thornal's position. Three promoted leaders assumed responsibilities effective October 1 as the company sharpened its U.S. commercial and robotics focus. The operating test is whether that transition improves productivity without disruption; Q2 knee sales grew only 0.1% organically on a constant-currency basis, versus 4.0% company-wide. Year-end is a monitoring marker. [#8-K-2026-09-08] Company leadership update Company Q2 release
Prob 55% • Move 4% • Priced-in 65%

Long-term Catalysts

Months to a year

ROSA Shoulder adoption after clearance
2027-06-30
Zimmer Biomet reported FDA 510(k) clearance and initial cases for its next-generation ROSA Shoulder system. Broader surgeon and hospital adoption—not clearance alone—is the unresolved commercial catalyst. June 30, 2027 is an analyst monitoring marker, not company launch guidance. [#SEC-8K-2026-08-05] Company Q2 release
Prob 55% • Move 5% • Priced-in 40%
Expected 2027 Monogram robot launch
2027-12-31
The company says it is expanding its specialized robotics salesforce ahead of an expected 2027 launch of the Monogram next-generation orthopedic robot. Timing, uptake and economics remain unproven; December 31 is only a year-end monitoring marker. Company leadership update
Prob 50% • Move 7% • Priced-in 35%

Risks

Adjusted Q2 EPS was unchanged year over year despite higher sales; guidance execution and margin conversion remain important. [#SEC-8K-2026-08-05]
Americas leadership restructuring could disrupt sales execution before productivity benefits appear. [#8-K-2026-09-08]
Knee sales lagged overall Q2 organic growth, raising the bar for commercial improvement. Company Q2 release
ROSA Shoulder adoption and the expected 2027 Monogram launch are not yet demonstrated revenue inflections. Company leadership update

Peers

Symbol	Summary
ENOV	Direct reconstructive-joint comparator: Enovis Surgical lists EMPOWR knee implants and AltiVate shoulder implants, making knee performance and shoulder adoption relevant comparisons. Its scale and business mix differ from ZBH's. Enovis Surgical portfolio
JNJ	DePuy Synthes competes directly in robotic-assisted knee replacement with its VELYS system and ATTUNE knee implant. Compare that orthopedic franchise rather than treating diversified Johnson & Johnson as a pure-play valuation peer. J&J MedTech VELYS product page
SYK	Direct orthopedic implant and surgical-robotics comparator: Stryker markets hip and knee implants alongside Mako SmartRobotics. Compare joint-replacement and robotics execution, while adjusting any company-wide valuation comparison for Stryker's broader mix. Stryker joint-replacement portfolio

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-10

Loading AI feed…

Symbol

Summary

ENOV

Direct reconstructive-joint comparator: Enovis Surgical lists EMPOWR knee implants and AltiVate shoulder implants, making knee performance and shoulder adoption relevant comparisons. Its scale and business mix differ from ZBH's. Enovis Surgical portfolio

JNJ

DePuy Synthes competes directly in robotic-assisted knee replacement with its VELYS system and ATTUNE knee implant. Compare that orthopedic franchise rather than treating diversified Johnson & Johnson as a pure-play valuation peer. J&J MedTech VELYS product page

SYK

Direct orthopedic implant and surgical-robotics comparator: Stryker markets hip and knee implants alongside Mako SmartRobotics. Compare joint-replacement and robotics execution, while adjusting any company-wide valuation comparison for Stryker's broader mix. Stryker joint-replacement portfolio